Skip to main content
Erschienen in: BMC Infectious Diseases 1/2021

Open Access 01.12.2021 | Research article

Clinical features of parainfluenza infections among young children hospitalized for acute respiratory illness in Amman, Jordan

verfasst von: Leigh M. Howard, Danielle A. Rankin, Andrew J. Spieker, Wenying Gu, Zaid Haddadin, Varvara Probst, Herdi Rahman, Rendie McHenry, Claudia Guevara Pulido, John V. Williams, Samir Faouri, Asem Shehabi, Najwa Khuri-Bulos, Natasha B. Halasa

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2021

Abstract

Background

Parainfluenza virus (PIV) is a leading cause of acute respiratory illness (ARI) in children. However, few studies have characterized the clinical features and outcomes associated with PIV infections among young children in the Middle East.

Methods

We conducted hospital-based surveillance for ARI among children < 2 years of age in a large referral hospital in Amman, Jordan. We systematically collected clinical data and respiratory specimens for pathogen detection using reverse transcription polymerase chain reaction. We compared clinical features of PIV-associated ARI among individual serotypes 1, 2, 3, and 4 and among PIV infections compared with other viral ARI and ARI with no virus detected. We also compared the odds of supplemental oxygen use using logistic regression.

Results

PIV was detected in 221/3168 (7.0%) children hospitalized with ARI. PIV-3 was the most commonly detected serotype (125/221; 57%). Individual clinical features of PIV infections varied little by individual serotype, although admission diagnosis of ‘croup’ was only associated with PIV-1 and PIV-2. Children with PIV-associated ARI had lower frequency of cough (71% vs 83%; p < 0.001) and wheezing (53% vs 60% p < 0.001) than children with ARI associated with other viruses. We did not find a significant difference in supplemental oxygen use between children with PIV-associated infections (adjusted odds ratio [aOR] 1.12, 95% CI 0.66–1.89, p = 0.68) and infections in which no virus was detected.

Conclusions

PIV is frequently associated with ARI requiring hospitalization in young Jordanian children. Substantial overlap in clinical features may preclude distinguishing PIV infections from other viral infections at presentation.
Begleitmaterial
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12879-021-06001-1.
Najwa Khuri-Bulos and Natasha B. Halasa denotes co-senior author.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AdV
Human adenovirus
aOR
Adjusted odds ratio
ARI
Acute respiratory illness
CI
Confidence interval
EPIC
Etiology of Pneumonia in the Community
HCoV
Human coronaviruses
HMPV
Human metapneumovirus
HRV
Human rhinovirus
ICU
Intensive care unit
LOS
Length of stay
LRTI
Lower respiratory tract illness
MERS-CoV
Middle East respiratory syndrome coronavirus
MV
Mechanical ventilation
PERCH
Pneumonia Etiology for Child Health
PIV
Parainfluenza virus
REDCap
Research Electronic Data Capture
RSV
Respiratory syncytial virus
URI
Upper respiratory infection
UMCs
Underlying medical conditions

Background

Acute respiratory illnesses (ARI) are a leading cause of morbidity and mortality among children globally, and respiratory viruses are increasingly recognized as important etiologies of severe ARI in young children [1, 2]. Parainfluenza virus (PIV) is commonly detected in ARI across all age groups, with highest prevalence typically occurring among young children [26]. Clinical features associated with PIV infections range from asymptomatic infection or mild upper respiratory disease to lower respiratory tract illness, with symptoms typically more severe among infants and young children than older children and adults [79].
Four distinct serotypes of PIV have been associated with human disease, and individual serotypes may vary with regards to certain clinical features. PIV-3 is the most prevalent serotype and is often associated with lower respiratory disease, including bronchiolitis and pneumonia, while PIV-1 and PIV-2 infections in children are often associated with laryngotracheobronchitis (“croup”) [10, 11]. Due to difficulties in isolation and typical association with milder disease, PIV-4 has often been excluded from many epidemiologic surveillance studies [12], although with advancements in molecular diagnosis, there is increasing evidence that PIV-4 may be associated with more severe, lower respiratory tract disease [2]. Individual PIV serotypes may also vary in terms of their seasonal patterns of detection. In temperate regions, peak PIV-2 and PIV-3 detections typically occur annually in the late spring (April–June) and autumn (October–November), while PIV-1 exhibits biennial peaks later in the year in odd years [11, 13], although serotype-specific seasonality information is scarce in many regions [14].
Despite the importance of PIV as a common etiology of severe respiratory illnesses in children, many studies of PIV infections in children have focused on those with pneumonia and have excluded children with other forms of ARI [12, 15]. We conducted a prospective study of ARI-associated hospitalizations among young children < 2 years of age over a three-year period in Amman, Jordan. We sought to define the clinical features of PIV infections in young children and to compare these among serotypes 1, 2, 3, and 4 as well as with ARI associated with other respiratory viruses.

Methods

Study design and setting

We enrolled children less than 2 years of age admitted with ARI (fever and/or respiratory symptoms) to Al-Bashir Government Hospital in Amman, Jordan from March 2010 to March 2013. Detailed characterization of the study population, setting, and design have been previously published [16, 17]. Briefly, children were eligible if they were admitted with fever and/or a respiratory symptom (e.g. cough, shortness of breath, wheezing) and one of the following admission diagnoses: ARI, apnea, asthma exacerbation, bronchiolitis, bronchopneumonia, croup, cystic fibrosis exacerbation, febrile seizure, fever without localizing signs, respiratory distress, pneumonia, pneumonitis, pertussis, pertussis-like cough, rule-out sepsis (evaluation of neonates with fever), upper respiratory infection (URI) and/or a lower respiratory tract illness. Lower respiratory tract illness (LRTI) was defined as an admission diagnosis of asthma, bronchiolitis, bronchopneumonia, pneumonia, respiratory distress, or wheezing and/or the presence of retractions/accessory muscle use or wheezing on examination [16]. Children with neutropenia secondary to chemotherapy and newborns who had never been discharged from the hospital after birth were excluded from the study. Active, year-round, hospital-based surveillance was conducted to recruit eligible children during 5 days of each week (Sunday-Thursday) within 48 h of hospital admission.
Al-Bashir Hospital is the major government-run referral center that serves Amman (estimated population > 2 million). The hospital provided care for an estimated 50–60% of children residing in Amman during the study period [16]. During the study period, 11,230 of the 17,557 children (64%) admitted to the pediatric wards were under 2 years of age. Written informed consent was obtained from parents or guardians of children prior to enrollment and initiation of study activities. The institutional review boards of the University of Jordan, the Jordanian Ministry of Health, and Vanderbilt University approved the study. All methods were performed in accordance with relevant guidelines and regulations.

Data collection

After informed consent, trained local research staff interviewed parents/legal guardians in Arabic using a standardized questionnaire that included Arabic and English translations to record demographic, clinical, and socioeconomic data, including the presence of underlying medical conditions (UMCs) and household smoke (cigarette and/or hookah pipe) exposure. After hospital discharge, charts were abstracted for the following: antibiotic use, blood culture results, chest radiography results, oxygen use, intensive care unit (ICU) admission, mechanical ventilation (MV), length of stay (LOS) in the hospital, and status at discharge. All data were entered into a standardized, secure Research Electronic Data Capture (REDCap) database (Vanderbilt University, Nashville, Tennessee, USA). We performed data quality checks on a minimum of 10% of the charts and verified data from all case report forms after entry. The following were considered UMCs: diabetes, heart disease, Down syndrome, kidney disease, sickle cell disease, cystic fibrosis, cancer, genetic/metabolic, cerebral palsy, neurological, mental retardation/developmental delay, seizure disorder, chronic diarrhea (> 2 weeks), gastroesophageal reflux disease, immunodeficiency, asthma/reactive airway disease, or liver disease.

Sample collection and testing

Nasal and throat swabs were collected from enrolled subjects and combined in transport medium (M4RT, Remel, USA), aliquoted into MagMAX Lysis/Binding Solution Concentrate (Life Technologies, USA), snap-frozen and then stored at − 80 °C. Aliquots were shipped on dry ice to Nashville, Tennessee, USA, and were tested by individual single-plex RT-PCR for 16 viruses: respiratory syncytial virus (RSV); human rhinovirus (HRV); human metapneumovirus (HMPV); influenza (influenza) A, B and C; parainfluenza virus (PIV) 1, 2, 3, and 4; human adenovirus (AdV), human coronaviruses (HCoV) HKU1, OC43, 229E, and NL63, and Middle East respiratory syndrome coronavirus (MERS-CoV) [18].

Statistical analysis

We compared common clinical features and seasonality of detection in patients with PIV-1, PIV-2, PIV-3 and PIV-4-associated respiratory illness, as defined by detection of each PIV serotype from a respiratory sample by PCR, including co-detections of other respiratory viruses. Next, we compared features of PIV-only respiratory illness, excluding co-detections with other viruses, to ARI associated with detection of other viruses (sole or co-detection of hMPV, RSV, AdV, MERS-CoV, influenza, or HRV), and ARI with no virus detected. These categories were mutually exclusive. Chi-square and two sample t-tests allowing unequal variances were used to compare categorical and continuous variables, respectively, between groups.
Linear regression with robust standard errors was used to evaluate the association between ARI etiologic category (PIV, other viruses, no virus) and time to hospital discharge (hospital length of stay [LOS] measured in hours). Model covariates included age, sex, breastfeeding status, antibiotic use prior to admission, duration of symptoms prior to admission, smoke exposure, and presence of at least one UMC. Logistic regression with robust standard errors was used to evaluate the association between ARI etiologic category (PIV, other viruses, no virus) and the need for supplemental oxygen as a surrogate indicator of illness severity, using the same covariates as in the linear regression model. All analyses were conducted using statistical software StataIC 16.0 (StatCorp LLC, College Station, TX). For all statistical tests, we used a nominal significance level of α = 0.05.

Results

PIV-associated acute respiratory illness

Among 3168 children admitted with ARI and included in this study, PIV was detected by nasal/throat swab PCR in 221 (7.0%; Supplementary Figure 1). Other viruses were commonly co-detected with PIV (125/221, 57%; Fig. 1); most commonly HRV (24%), RSV (9%), and adenovirus (7%). PIV-3 was the most commonly detected of the PIV serotypes (128/221, 58%, Table 1), followed by PIV-4 (49/221; 22%), PIV-1 (34/221; 15%), and PIV-2 (13/221; 6%). PIV-3 and PIV-4 were codetected in 3 children. Three of 95 children with PIV infection from whom a blood culture was collected had a positive blood culture result [Staphylococcus aureus (22 day old with discharge diagnosis of sepsis; n = 1), Candida spp. (40 day old with discharge diagnoses of pneumonia and sepsis; n = 1), Micrococcus spp. (suspected contaminant; n = 1)].
Table 1
Characteristics of hospitalized children with PIV-1, PIV-2, PIV-3, and PIV-4 including co-detections with other pathogens
 
PIV-1
(n = 34)
No. (%)
PIV-2
(n = 13)
No. (%)
PIV-3a
(n = 125)
No. (%)
PIV-4a
(n = 46)
No. (%)
p-value
Female sex
16 (47.1)
6 (46.2)
48 (38.4)
21 (45.7)
0.714
Median age, months (IQR)
9.0 (3.5–16.1)
5.4 (2.6–8.6)
3.2 (1.7–8.9)
2.6 (1.7–9.1)
0.003
Age group
  < 6 months
13 (38.2)
7 (53.9)
80 (64.0)
29 (63.0)
0.028
 6 to < 12 months
7 (20.6)
5 (38.5)
23 (18.4)
8 (17.4)
 12 to < 24 months
14 (41.2)
1 (7.7)
22 (17.6)
9 (19.6)
Received influenza vaccine
0 (0)
0 (0)
1 (1.0)
0 (0)
0.861
Breastfed, any
30 (88.2)
13 (100)
92 (73.6)
37 (80.4)
0.059
Any underlying medical conditionb
3 (8.8)
2 (15.4)
19 (15.2)
6 (13.0)
0.810
Household smoke exposure
23 (67.7)
10 (76.9)
95 (76.0)
37 (80.4)
0.620
Symptom duration prior to admission, days (IQR)
3.5 (2–5)
2 (2–4)
3 (2–5)
2 (1–5)
0.253
Antibiotics prior to admission
17 (50.0)
3 (23.1)
42 (33.6)
19 (41.3)
0.210
Antibiotics during hospitalization
33 (97.1)
9 (69.2)
115 (92.0)
44 (95.7)
0.010
Clinical presentation
 Fever/feverishc
21 (61.8)
9 (69.2)
77 (61.6)
27 (58.7)
0.923
 Coughc
30 (88.2)
10 (76.9)
90 (72.0)
36 (78.3)
0.258
 Shortness of breathc
23 (67.7)
9 (69.2)
55 (44.0)
28 (60.9)
0.045
 Flaring/Retractionsd
14 (41.2)
5 (38.5)
36 (28.8)
15 (32.6)
0.541
 Retractions, onlyd
2 (5.9)
1 (7.7)
4 (3.2)
4 (8.7)
0.492
 Wheezingd
20 (58.8)
6 (46.2)
62 (49.6)
22 (47.8)
0.750
Admission diagnosis
 Reactive airway disease
3 (8.8)
1 (7.7)
4 (3.2)
1 (2.2)
0.387
 Bronchiolitis
6 (17.7)
3 (23.1)
14 (11.2)
10 (21.7)
0.275
 Bronchopneumonia
14 (41.2)
4 (30.8)
48 (38.4)
13 (28.3)
0.563
 Croup
2 (5.9)
1 (7.7)
0 (0.0)
0 (0.0)
0.010
 Febrile seizure
2 (5.9)
1 (7.7)
4 (3.2)
1 (2.2)
0.697
 Pneumonia
4 (11.8)
0 (0.0)
12 (9.6)
5 (10.9)
0.649
 Pertussis-like cough
0 (0.0)
0 (0.0)
9 (7.2)
4 (8.7)
0.269
 Rule-out sepsis
5 (14.7)
3 (23.1)
40 (32.0)
11 (23.9)
0.211
Classified as LRTI
28 (82.4)
9 (69.2)
84 (67.2)
31 (67.4)
0.382
Chest radiograph
 Abnormal
23/31 (74.2)
8/11 (72.7)
78/116 (67.2)
28/44 (63.4)
0.785
Required supplemental oxygen
11 (32.4)
2 (15.4)
35 (28.0)
14 (30.4)
0.695
Required ICU admission
5 (14.7)
0 (0.0)
9 (7.2)
3 (6.5)
0.318
Required mechanical ventilation
2 (5.9)
0 (0.0)
5 (4.0)
0 (0.0)
0.393
Length of stay (days), median (IQR)
3 (2–6)
5 (3–8)
6 (3–8)
5 (3–8)
0.161
Codetected with ≥1 other virus
21 (61.8)
8 (61.5)
64 (51.2)
30 (65.2)
0.338
Death
0 (0.0)
0 (0.0)
0 (0.0)
1 (2.2)
0.431
a Individual serotypes detected and distinguished by PCR; excludes 3 cases of codetection of PIV-3 and PIV-4
+ p < 0.05 considered statistically significant, indicated by bold text
b UMC defined as at least one of the following: diabetes, heart disease, Down syndrome, kidney disease, sickle cell disease, cystic fibrosis, cancer, genetic/metabolic, cerebral palsy, neurological, mental retardation/developmental delay, seizure disorder, chronic diarrhea (eg, > 2 weeks), gastroesophageal reflux disease, immunodeficiency, asthma/reactive airway disease, liver disease
c Reported by parent/legal guardian
d Collected through clinical exam

Seasonality of PIV detections

While PIV detections occurred throughout the year during our study, peak PIV detections in 2011 occurred in November–December (Fig. 2), while in 2012 a earlier peak occurred in July in addition to the winter (November 2012 to January 2013) peak. PIV detections in the spring-summer months were primarily contributed by PIV-3. The majority of PIV-1 detections occurred in 2011.

Clinical features of PIV-1, PIV-2, PIV-3, and PIV-4 infections

The clinical features of infections associated with individual PIV serotypes, inclusive of co-detections with other viruses, are displayed in Table 1. The median age of hospitalized children with PIV-3 and PIV-4 detections was significantly lower than those with PIV-1 or PIV-2 (Table 1). The proportion of children with an underlying medical condition was similar among children with infection associated with each of the PIV serotypes. Greater than 90% of children with PIV-1, PIV-3, and PIV-4 infections received antibiotics during hospitalization, compared to only 69% of those hospitalized with PIV-2 associated infections (Table 1). The clinical symptoms of PIV infections did not vary significantly according to individual serotype. Bronchopneumonia, rule-out sepsis, and bronchiolitis were the most common admission diagnoses assigned to PIV 1–4 infections; an admission diagnosis of “croup” was only assigned to admissions associated with PIV-1 or PIV-2, while “pertussis-like cough” was assigned only to PIV-3 and PIV-4 associated admissions. Only 2/13 (15%) children with PIV-2-associated infections required supplemental oxygen, compared to 32, 28, and 30% of children with PIV-1, PIV-3, and PIV-4-associated infections, respectively, however this difference was not statistically significant (p = 0.695). The clinical features of infections associated with individual PIV serotypes, excluding co-detections with other viruses, are displayed in Supplementary Table 1.

Features of PIV-associated infections compared to other viral infections

After exclusion of infections in which PIV was codetected with other respiratory viruses, the clinical features of children with PIV-only associated ARI compared to other respiratory viruses or no virus detection are displayed in Table 2. Compared to both groups, PIV-only children had higher mean age (Table 2). Children with PIV had a higher frequency of fever (63%) than those with ARI associated with other viruses (53%; p < 0.001), but they had a lower frequency of nasal flaring/chest retractions (33% vs. 46%, p < 0.001) and wheezing (53% vs. 60%, p < 0.001). A higher frequency of children with PIV-only and other virus-associated ARI met the LRTI definition, had longer symptom onset prior to admission, and had higher occurrence of cough, nasal flaring/chest retractions, and wheezing compared to children with no virus detected. The most common admission diagnoses assigned to PIV-only group in descending order were bronchopneumonia, rule-out sepsis, pneumonia, and bronchiolitis while bronchopneumonia, bronchiolitis, rule-out sepsis, pneumonia were the most common admission diagnoses for any PIV detection (Tables 1 and 2). The frequency of croup as an admission diagnosis was higher in children with PIV-only compared to the other groups, while the frequencies of bronchiolitis, bronchopneumonia, and pneumonia were higher among the PIV-only and other virus group compared to the children in whom no virus was detected. In unadjusted comparisons, fewer children with PIV-associated infection required supplemental oxygen (23%) or ICU admission (6%) than those with ARI associated with other viruses (35 and 9%, respectively; p < 0.001 and p = 0.048).
Table 2
Characteristics of hospitalized children with PIV-associated respiratory illness compared to other-viral and virus-negative respiratory illness
 
PIV only*
(n = 96)
No. (%)
Other virus, not PIV
(n = 2413)
No. (%)
No virus
(n = 534)
No. (%)
p-value+
Female sex
39 (40.6)
954 (39.5)
209 (39.1)
0.960
Median age, months (IQR)
4.2 (1.7–10.8)
3.8 (1.8–8.5)
2.3 (1.1–7.6)
< 0.001
Age group
  < 6 months
54 (56.3)
1544 (64.0)
382 (71.5)
0.001
 6 to < 12 months
19 (19.8)
499 (20.7)
79 (14.8)
 
 12 to < 24 months
23 (24.0)
370 (15.3)
73 (13.7)
 
Received influenza vaccine
0 (0.0)
5 (0.21)
1 (0.2)
0.264
Breastfed
78 (81.3)
2034 (84.3)
453 (84.8)
0.674
Any underlying medical conditiona
12 (12.5)
269 (11.2)
75 (14.0)
0.164
Asthma/reactive airway disease
1 (1.0)
65 (2.7)
10 (1.9)
0.285
Household smoke exposure
74 (77.1)
1851 (76.7)
406 (76.0)
0.939
Symptom duration prior to admission
3 (1.5–4)
3 (2–5)
2 (1–3)
0.002
Antibiotics during hospitalization
89 (92.7)
2193 (90.9)
489 (91.6)
0.746
Clinical presentation
 Fever/feverishb
60 (62.5)
1279 (53.0)
347 (65.0)
< 0.001
 Coughb
68 (70.8)
1990 (82.5)
207 (38.8)
< 0.001
 Shortness of breathb
48 (50.0)
1543 (64.0)
172 (32.2)
< 0.001
 Flaring/Retractionsc
32 (33.3)
1099 (45.5)
121 (22.7)
< 0.001
 Retractions, onlyc
5 (5.2)
240 (10.0)
30 (5.6)
0.003
 Wheezingc
51 (53.1)
1455 (60.3)
189 (35.4)
< 0.001
Admission diagnosis
 Reactive airway disease
4 (4.2)
123 (5.1)
14 (2.6)
0.047
 Bronchiolitis
10 (10.4)
483 (20.0)
31 (5.8)
< 0.001
 Bronchopneumonia
34 (35.4)
818 (33.9)
121 (22.7)
< 0.001
 Croup
2 (2.1)
6 (0.3)
1 (0.2)
0.005
 Febrile seizure
5 (5.2)
47 (2.0)
28 (5.2)
< 0.001
 Pneumonia
14 (14.6)
338 (14.0)
34 (6.4)
< 0.001
 Pneumonitis
0 (0.0)
1 (0.04)
1 (0.19)
0.477
 Pertussis-like cough
6 (6.3)
182 (7.5)
22 (4.1)
0.018
 Rule-out sepsis
27 (28.1)
559 (23.2)
282 (52.8)
< 0.001
Classified as LRTI
68 (70.8)
1878 (77.8)
230 (43.1)
< 0.001
Chest radiograph
 Abnormal
60/90 (66.7)
1734/2302 (75.3)
203/454 (44.7)
< 0.001
Required supplemental oxygen
22 (22.9)
829/2384 (34.8)
122/532 (22.9)
< 0.001
Required ICU admission
6 (6.3)
205 (8.5)
62 (11.6)
0.048
Required mechanical ventilation
3 (3.1)
82/2383 (3.4)
22/532 (4.1)
0.717
Length of stay (days), median (IQR)
5 (3–8)
5 (3–7)
5 (3–8)
0.154
Death
0 (0.0)
21 (1.0)
9 (2.0)
0.140
* One child with both PIV 3 and PIV 4 serotypes is included in the PIV only group
+ p < 0.05 considered statistically significant, indicated by bold text
a UMC defined as at least one of the following: diabetes, heart disease, Down syndrome, kidney disease, sickle cell disease, cystic fibrosis, cancer, genetic/metabolic, cerebral palsy, neurological, mental retardation/developmental delay, seizure disorder, chronic diarrhea (eg, > 2 weeks), gastroesophageal reflux disease, immunodeficiency, asthma/reactive airway disease, liver disease
b Reported by parent/legal guardian
c Collected through clinical exam

Multivariable analysis: hospital length of stay

We used linear regression to compare the mean length of hospital stay between children with PIV-associated and other viral ARI compared to ARI in which no viruses were detected (reference), adjusting for age, sex, breastfeeding status, antibiotic use prior to admission, duration of symptoms prior to admission, smoke exposure, and presence of at least one UMC. Based on this model, we estimated the mean hospital length of stay to be 0.51 days longer in the PIV group compared to those with no viruses detected (95% confidence interval [CI] -0.50, 1.52, p = 0.32). Further, we estimated the mean hospital length of stay to be 0.30 days shorter for ARI associated with other viruses compared to ARI in which no viruses were detected (95% CI -0.70, 0.10, p = 0.14).

Multivariable analysis: supplemental oxygen use

We did not find sufficient evidence of a difference in supplemental oxygen use between children with PIV-associated infections (reference) adjusted odds ratio and infections in which no virus was detected (adjusted odds ratio [aOR] 0.90, 95% CI 0.53–1.53, p = 0.70; Fig. 3). Infections with viruses other than PIV and the presence of an underlying medical condition were associated with significantly increased odds of supplemental oxygen use (aOR 1.79, 95% CI 1.09–2.92, p = 0.02 and aOR 2.08, 95% CI 1.62–2.67, p < 0.001, respectively).

Discussion

While RSV [16] and HMPV [19] have previously been recognized as important etiologies of ARI associated with hospitalization in young Jordanian children, our findings underscore the importance of PIV as an etiology of ARI and LRTI requiring hospitalization in young children in Jordan. We identified a higher frequency of fever and a lower frequency of nasal flaring/retractions and wheezing in children with PIV compared to other ARI in unadjusted analyses, and significantly lower odds of supplemental oxygen use in children with PIV compared to other viral infections. However, there was substantial overlap in the presenting signs and symptoms of PIV infections and those of other viral etiologies, limiting the ability to distinguish these etiologies clinically at the time of presentation. We also found substantial overlap in the clinical features of infections associated with individual PIV serotypes but substantial variability in the seasonality of individual PIV serotype detections. PIV-1 and PIV-2 were the only PIV serotypes associated with an admission diagnosis of croup, consistent with literature that these serotypes are the most common pathogens associated with laryngotrachobronchitis [8]. In addition, our report is among the first to include clinical and epidemiological information regarding PIV-4 infections in young children in the Middle East.
In our study, PIV was detected in 7% of children who presented with both fever and/or respiratory symptoms. Recent reports have focused on the role of PIV in respiratory illnesses in children, but many of these have focused on severe illnesses including pneumonia. For example, in the multicenter Etiology of Pneumonia in the Community (EPIC) study in the United States, PIV infection was detected in 6.6% of cases of radiographically-confirmed pneumonia in hospitalized children, and these infections were associated with similar severity as infections with other respiratory viruses [12]. In the international Pneumonia Etiology for Child Health (PERCH) study, PIV (including PIV-4) was detected in 12% of pneumonia cases and 5.9% of controls, and PIV was among the five most common pathogens in five of the seven study sites, which did not include the Middle East [2, 15]. Our results were consistent with this study, reporting that PIV was the fifth most commonly detected virus after RSV, HRV, AdV, and HMPV [17]. Although our study was limited to a single center, we uniquely included the full spectrum of respiratory conditions associated with PIV, such as laryngotracheobronchitis and bronchiolitis, in a setting in which household smoke exposure, an established risk factor associated with acute respiratory illnesses and respiratory outcomes in children, [20, 21] was relatively high [12].
We observed the majority of PIV-1 detections were in 2011, an odd year, which is consistent with prior reports of seasonal detections of PIV-1 from United States, in which PIV-1 often exhibits biennial peaks [11, 22]. In 2012, the earlier peak was dominated by PIV-3, consistent with other studies that report that PIV-3 primarily circulates annually during the summer months [11, 22]. We did not see predominant circulation of PIV-2 during even years although detection of few cases of PIV-2 in our hospitalized cohort limited seasonality assessment for this serotype, for which many milder infections managed in the outpatient setting may not have been captured. Few studies have reported the seasonal patterns of detection of PIV-4; we primarily observed detections in the late autumn and winter months in our cohort.
Our study has several strengths, including active surveillance and comprehensive respiratory viral testing. The study also has several limitations. Lower respiratory tract specimens were infrequently available. Healthy controls were not included. Although PIV is thought to be infrequently detected in asymptomatic young children [23], it has been detected more frequently among healthy controls in other studies [2]. Frequent co-detections of PIV with other respiratory viruses limited our ability to compare sole detections of PIV to other viruses and to compare the clinical features of individual PIV serotypes with robust conclusions.

Conclusions

In summary, PIV infections were common in children hospitalized with ARI. There were few distinguishing clinical features at presentation, yet several differences in seasonal detection patterns observed, according to PIV serotype. No clinical characteristics were identified that could reliably distinguish PIV from ARI caused by other viruses at presentation, although PIV-associated ARI were less frequently associated with supplemental oxygen use. Our findings suggest that all four PIV serotypes are important etiologies of ARI associated with hospitalization in young Jordanian children. Such surveillance may provide more conclusive characterization of the epidemiology of PIV in the Middle East to support the need for evaluation of future vaccines and antivirals in this region [24, 25].

Acknowledgments

We thank the patients who consented for their children to participate. We also would like to thank Al-Bashir Hospital and Jordan University for their collaboration in this surveillance project and our research recruiters: Hanan Amin, Amani Altaber, Hana’a Khalaf, Isra’aKharbat, Darin Yasin, Shireen Issa, and Nurse Sabah Gharbli, and the doctors at Al-Bashir Hospital.

Declarations

This study was given ethical approval by the University of Jordan, the Jordanian Ministry of Health, and Vanderbilt University. Informed consent was obtained from parents and/or the guardians of the children enrolled in this study.
Not applicable.

Competing interests

Natasha Halasa, MD, MPH receives grant support from Sanofi, Quidel, and speaker compensation from an education grant supported by Genentech. Sanofi also donated vaccines and influenza antibody testing for influenza vaccine trial. John Williams, MD is on the Scientific Advisory Board for Quidel, Independent Data Safely Monitoring Committee for GlaxoSmithKline, and Scientific Advisory Board for ID Connect. All of the other authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Supplementary Information

Literatur
2.
Zurück zum Zitat Pneumonia Etiology Research for Child Health Study G. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019. Pneumonia Etiology Research for Child Health Study G. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019.
12.
15.
Zurück zum Zitat Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, et al. Is Higher Viral Load in the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH Study. Clin Infect Dis. 2017;64(suppl_3):S337–S46.CrossRef Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, et al. Is Higher Viral Load in the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH Study. Clin Infect Dis. 2017;64(suppl_3):S337–S46.CrossRef
23.
Zurück zum Zitat Howard LM, Johnson M, Williams JV, Zhu Y, Gil AI, Edwards KM, et al. Respiratory Viral Detections During Symptomatic and Asymptomatic Periods in Young Andean Children. Pediatr Infect Dis J. 2015. Howard LM, Johnson M, Williams JV, Zhu Y, Gil AI, Edwards KM, et al. Respiratory Viral Detections During Symptomatic and Asymptomatic Periods in Young Andean Children. Pediatr Infect Dis J. 2015.
Metadaten
Titel
Clinical features of parainfluenza infections among young children hospitalized for acute respiratory illness in Amman, Jordan
verfasst von
Leigh M. Howard
Danielle A. Rankin
Andrew J. Spieker
Wenying Gu
Zaid Haddadin
Varvara Probst
Herdi Rahman
Rendie McHenry
Claudia Guevara Pulido
John V. Williams
Samir Faouri
Asem Shehabi
Najwa Khuri-Bulos
Natasha B. Halasa
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2021
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06001-1

Weitere Artikel der Ausgabe 1/2021

BMC Infectious Diseases 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.